Other analysts also recently issued research reports about the stock. HC Wainwright cut their price target on shares of Urovant Sciences from $33.00 to $28.00 and set a buy rating for the company in a report on Friday, June 19th. Zacks Investment Research downgraded shares of Urovant Sciences from a hold rating to a sell rating in a report on Saturday, June 27th.
UROV traded down $0.32 on Thursday, reaching $8.05. The company had a trading volume of 9 shares, compared to its average volume of 69,907. Urovant Sciences has a fifty-two week low of $6.55 and a fifty-two week high of $15.98. The stock has a market cap of $260.68 million, a P/E ratio of -1.72 and a beta of 1.29. The company’s fifty day moving average is $8.99 and its 200 day moving average is $10.02.
Urovant Sciences (NASDAQ:UROV) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.99) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.36) by $0.37. Research analysts forecast that Urovant Sciences will post -6.78 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the stock. Marshall Wace North America L.P. bought a new position in Urovant Sciences in the 1st quarter valued at approximately $49,000. Royal Bank of Canada lifted its stake in Urovant Sciences by 2,950.8% in the 1st quarter. Royal Bank of Canada now owns 9,305 shares of the company’s stock valued at $86,000 after purchasing an additional 9,000 shares during the last quarter. Vigilare Wealth Management bought a new position in Urovant Sciences in the 2nd quarter valued at approximately $100,000. First Trust Advisors LP lifted its stake in Urovant Sciences by 8.1% in the 2nd quarter. First Trust Advisors LP now owns 15,299 shares of the company’s stock valued at $151,000 after purchasing an additional 1,144 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Urovant Sciences in the 1st quarter valued at approximately $325,000. 23.81% of the stock is owned by institutional investors and hedge funds.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: How to invest using market indexes
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.